Key Drivers
- High profitability
- Strong FCF
- Elevated leverage
AIAI Summary
IQVIA's investment case has materially shifted: upside now hinges less on steady organic CRO growth and more on successful AI/data commercialization and consistent backlog-to-revenue conversion, so investors should track early AI monetization metrics, book-to-bill/backlog conversion rates, and any tangible progress on deleveraging. If AI adoption and booking conversion accelerate while cash conversion stays high, the stock re-rates; if guidance misses, pass-through margin pressure, or backlog slippage persist, downside risk is amplified.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Strong FCF
- •Elevated leverage
IQV: strong profitability and cash generation (high ROE/ROIC, healthy margins, $2.13B FCF) but materially leveraged with tight short-term liquidity and heavy intangibles, so returns are attractive only if you accept balance-sheet and solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Flat momentum
- •Intraperiod rebound
- •Range consolidation
Over the last month IQV has traded flat overall, showing a sharp rebound from $161.91 to $178.55 then a pullback and consolidation around $162–$168, with support near $162–$165 and resistance near $177–$180 keeping upside capped unless buyers push a decisive breakout.
Sharp intra-period rebound from $161.91 to $178.55 on 2026-03-09 indicating short-term buying interest
Sentiment & News
Key News Insights:
- •Strong bookings
- •Guidance shortfall
- •Active flows
IQVIA posted robust Q4/FY25 results with near‑100% cash conversion and a $32.7B backlog, but a below‑consensus 2026 EPS guide triggered a selloff amid mixed institutional flows.
Solid operating performance underpins long‑term value, but expect near‑term share pressure until guidance concerns are resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings